CDX2 Antibody (rCDX2/1690) [DyLight 650]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-08737C
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Immunohistochemistry-Paraffin
Label
DyLight 650 (Excitation = 652 nm, Emission = 672 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # rCDX2/1690
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant fragment (around aa150-249) of human CDX2 protein (exact sequence is proprietary) (Uniprot: Q99626)
Localization
Nuclear
Marker
GI Epithelial Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for CDX2 Antibody (rCDX2/1690) [DyLight 650]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CDX2
Long Name
Caudal-type Homeobox Transcription Factor 2
Alternate Names
CDX3
Gene Symbol
CDX2
Additional CDX2 Products
Product Documents for CDX2 Antibody (rCDX2/1690) [DyLight 650]
Product Specific Notices for CDX2 Antibody (rCDX2/1690) [DyLight 650]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...